Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Davis, Vanessa W ^a   Schiller, Daniel E ^a   Eurich, Dean ^a   Bathe, Oliver F ^b   Sawyer, Michael B ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLNICOTINAMIDE; 2 AMINOBUTYRIC ACID; 4 HYDROXYPHENYLACETIC ACID; ACETONE; ACETYLCARNITINE; ACONITIC ACID; ADIPIC ACID; ASCORBIC ACID; CHOLINE; DIMETHYLAMINE; FUCOSE; GLUCOSE; HYPOXANTHINE; METHANOL; PYRIDOXIC ACID; TAURINE; THREONINE; TRIGONELLINE; TRIMETHYLAMINE OXIDE; TRYPTOPHAN; XYLOSE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER SCREENING; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; METABOLOMICS; PANCREAS ADENOCARCINOMA; PATTERN RECOGNITION; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY METABOLOMICS; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; FOLLOW UP; METABOLOME; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR INVASION; URINE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; ROC CURVE;

EID: 84892805927     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2686-7     Document Type: Article

References (53)

1. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-44.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-17.
3. Bathe OF, Shaykhutdinov R, Kopciuk K et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev. 2011;20:140-7.
4. Greer JB, Lynch HT, Brand RE. Hereditary pancreatic cancer: a clinical perspective. Best Pract Res Clin Gastroenterol. 2009;23:159-70.
5. Lynch HT, Fitzsimmons ML, Smyrk TC, et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol. 1990;85:54-60.
6. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol. 2005;6:437-45.
7. German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics. 2005;1:3-9.
8. Fang F, He X, Deng H, et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci. 2007;98:1678-82.
9. Napoli C, Sperandio N, Lawlor RT, et al. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-83.
10. Nishijima T, Nishina M, Fujiwara K. Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies. Jpn J Clin Oncol. 1997;27:13-7.
11. OuYang D, Xu J, Huang H, Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol. 2011;165:148-54.
12. Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.
13. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Comm Mass Spectrom. 2010;24:613-20.
14. Wen H, Yoo SS, Kang J, et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2010;52:228-33.
15. Slupsky CM, Rankin KN, Wagner J, et al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem. 2007;79:6995-7004.
16. Eisner R, Stretch C, Eastman T, et al. Learning to predict cancerassociated skeletal muscle wasting from H-NMR Profiles of urinary metabolomics. Metabolomics. 2011;7:9.
17. McKay RT. Recent advances in solvent suppression for solution NMR: a practical reference. Ann Rep NMR Spectrosc. 2009;66:43.
18. Keifer PA. 90-Degree pulse width calibrations: how to read a pulse width array. Concepts Magn Reson. 1999;11:15.
19. Wu PS, Otting G. Rapid pulse length determination in high-resolution NMR. J Magn Reson. 2005;176:115-9.
20. Kumar A, Ernst RR, Wuthrich K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem Biophys Res Comm. 1980;95:1-6.
21. Wishart SD. Quantitative metabolomics using NMR. Trends Anal Chem. 2008;27:9.
22. Weljie AM, Newton J, Mercier P, et al. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem. 2006;78:4430-42.
23. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469-79.
24. Bylesjo MR, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometrics. 2006;20:10.
25. Eriksson L, Johansson E, Kettaneth-Wold N, Trygg J, Wilkstrom C, Wold S. Multivariate and megavariate data analysis advanced applications and extensions (part I and II). Umea: Umetrics, Inc.; 2006.
26. Pesarin F. Multivariate permutation tests: with applications in biostatistics. New York: Wiley; 2001.
27. Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference and prediction: with 200 fullcolor illustrations. New York: Springer; 2001.
28. Lee MX, Saif MW. Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP. 2009;10:104-8.
29. Fry LC, Monkemuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883-90.
30. Markers EGoT. Tumor markers in gastrointestinal cancers- EGTM recommendations. Anticancer Res. 1999;19:2811-15.
31. Pleskow DK, Berger HJ, Gyves J. Evaluation of a serological marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704-9.
32. Cwik G, Wallner G, Skoczylas T, et al. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141:968-73.
33. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA19-9 determination in the management of pancreatic cancer. Hepato-gastroenterology. 1996;43:710-3.
34. Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9:1286-92.
35. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-3.
36. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512-20.
37. Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:539-44.
38. Kilic M, Gocmen E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg. 2006;49:241-4.
39. Abraham SC, Wilentz RE, Yeo CJ, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol. 2003;27:110-20.
40. Kennedy T, Preczewski L, Stocker SJ, et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg. 2006;191:437-41.
41. Aranha GV, Hodul PJ, Creech S, Jacobs W. Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy. J Am Coll Surg. 2003;197:223-31.
42. Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004;110:902-6.
43. Lynch HT, Fitzsimmons ML, McClellan J, et al. Familial pancreatic cancer (part II): surveillance, diagnostic tests, and surgical strategies. Nebraska Med J. 1990;75:130-3.
44. Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer. 2003;103:525-30.
45. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15:280-7.
46. Davis VW, Bathe OF, Schiller DE, et al. Metabolomics and surgical oncology: potential role for small molecule biomarkers. J Surg Oncol. 2011;103:451-9.
47. Atherton HJ, Bailey NJ, Zhang W, et al. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics. 2006;27:178-86.
48. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009;8:352-61.
49. Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008;7:72.
50. Wang J, Ma C, Liao Z, et al. Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples. World J Gastroenterol. 2011;17:2126-30.
51. Fearon KC, Barber MD, Falconer JS, et al. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999;23:584-8.
52. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcogenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population- based study. Lancet Oncol. 2008;9:629-35.
53. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61.